Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    20130876 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine
Condition: Pancreatic Cancer
Interventions: Biological: bevacizumab;   Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis

Indicates status has not been verified in more than two years